Use of rituximab in refractory autoimmune thrombocytopenia following an autologous stem cell transplant

Hematology
Samantha PriceRamin Altaha

Abstract

Immune thrombocytopenia is well recognized post both allogeneic and autologous transplantation. The diagnosis can be difficult as there are generally several complicating features, including delayed marrow recovery and the use of multiple therapies. Treatment can be difficult and conventional approaches are often unsuccessful. We describe a case of presumed immune thrombocytopenia post autologous stem cell transplantation, who appeared to respond to the monoclonal B-cell antibody, rituxmab, which is being increasingly recognized as a therapeutic option in a variety of autoimmune disorders.

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.